An overview of glycopyrrolate/eFlow® CS in COPD

References

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of COPD. 2018 [cited 2018 Mar 05]. Available from: http://goldcopd.org/.
   Google Scholar
• Barnes PJ, Burney PGJ, Silverman EK, et al. Chronic obstructive pulmonary disease. Nat Rev Dis Primers. 2015;1:15076.
   PubMed Web of Science ®Google Scholar
• MacNee W. Pathology, pathogenesis, and pathophysiology. Bmj. 2006;332(7551):1202–1204.
   Web of Science ®Google Scholar
• Guarascio AJ, Ray SM, Finch CK, et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon Outcomes Res. 2013;5:235–245.
   PubMedGoogle Scholar
• Wheaton AG, Cunningham TJ, Ford ES, et al. Employment and activity limitations among adults with chronic obstructive pulmonary disease–United States, 2013. MMWR Morb Mortal Wkly Rep. 2015;64(11):289–295.
   PubMed Web of Science ®Google Scholar
• Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the global burden of disease study 2015. Lancet. 2016;388(10053):1459–1544.
   PubMed Web of Science ®Google Scholar
• European Lung Foundation ERS. Lung health in Europe: facts and figures. 2013 [ cited 2018 Feb 22]. Available from: http://www.europeanlung.org/assets/files/publications/lung_health_in_europe_facts_and_figures_web.pdf
   Google Scholar
• Cazzola M, Page CP, Calzetta L, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012;64(3):450–504.
   PubMed Web of Science ®Google Scholar
• Ficker JH, Rabe KF, Welte T. Role of dual bronchodilators in COPD: a review of the current evidence for indacaterol/glycopyrronium. Pulm Pharmacol Ther. 2017;45:19–33.
   PubMed Web of Science ®Google Scholar
• Salpeter SR. Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality. Int J Chron Obstruct Pulmon Dis. 2007;2(1):11–18.
   PubMedGoogle Scholar
• Santus P, Radovanovic D, Cristiano A, et al. Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease. Drug Des Devel Ther. 2017;11:3257–3271.
   PubMed Web of Science ®Google Scholar
• Lahousse L, Verhamme KM, Stricker BH, et al. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016;4(2):149–164.
   PubMed Web of Science ®Google Scholar
• Cazzola M, Page C, Matera MG. Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther. 2013;26(3):307–317.
   PubMed Web of Science ®Google Scholar
• Mastrodicasa MA, Droege CA, Mulhall AM, et al. Long acting muscarinic antagonists for the treatment of chronic obstructive pulmonary disease: a review of current and developing drugs. Expert Opin Investig Drugs. 2017;26(2):161–174.
   PubMed Web of Science ®Google Scholar
• Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185(2):393–399.
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364(12):1093–1103.
   PubMed Web of Science ®Google Scholar
• Horita N, Nagashima A, Kaneko T. Long-acting beta-agonists (LABA) combined with long-acting muscarinic antagonists or LABA combined with inhaled corticosteroids for patients with stable COPD. Jama. 2017;318(13):1274–1275.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017;12:907–922.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, D’Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). Copd. 2012;9(2):90–101.
   PubMedGoogle Scholar
• Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Investig. 2013;33(12):893–904.
   PubMed Web of Science ®Google Scholar
• Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12:55.
   PubMed Web of Science ®Google Scholar
• Gelb AF, Tashkin DP, Make BJ, et al. Long-term safety and efficacy of twice-daily aclidinium bromide in patients with COPD. Respir Med. 2013;107(12):1957–1965.
   PubMed Web of Science ®Google Scholar
• Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58(5):399–404.
   PubMed Web of Science ®Google Scholar
• Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19(2):217–224.
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543–1554.
   PubMed Web of Science ®Google Scholar
• LaForce C, Feldman G, Spangenthal S, et al. Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study. Int J Chron Obstruct Pulmon Dis. 2016;11:1233–1243.
   PubMed Web of Science ®Google Scholar
• Kerwin E, Siler TM, Korenblat P, et al. Efficacy and safety of twice-daily glycopyrrolate versus placebo in patients with COPD: the GEM2 study. Chronic Obstr Pulm Dis. 2016;3(2):549–559.
   PubMedGoogle Scholar
• Mahler DA, Gifford AH, Satti A, et al. Long-term safety of glycopyrrolate: a randomized study in patients with moderate-to-severe COPD (GEM3). Respir Med. 2016;115:39–45.
   PubMed Web of Science ®Google Scholar
• Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 mug compared with tiotropium 18 mug in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:719–730.
   PubMed Web of Science ®Google Scholar
• Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72–81.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62. 5/25mcg in COPD. Respir Med. 2013;107(10):1538–1546.
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78.
   PubMed Web of Science ®Google Scholar
• DePietro M, Gilbert I, Millette LA, et al. Inhalation device options for the management of chronic obstructive pulmonary disease. Postgrad Med. 2018;130(1):83–97.
   PubMed Web of Science ®Google Scholar
• Dolovich MB, Ahrens RC, Hess DR, et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American college of chest physicians/American college of asthma, allergy, and immunology. Chest. 2005;127(1):335–371.
   PubMed Web of Science ®Google Scholar
• Ibrahim M, Verma R, Garcia-Contreras L. Inhalation drug delivery devices: technology update. Med Devices (Auckl). 2015;8:131–139.
   PubMedGoogle Scholar
• Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care. 2010;55(7):911–921.
   PubMed Web of Science ®Google Scholar
• Sunovion Pharmaceuticals. Lonhala Magnair: highlights of prescribing information Marlborough, MA2018 [ cited 2018 February 5]. Available from: https://www.lonhalamagnair.com/LonhalaMagnair-Prescribing-Information.pdf
   Google Scholar
• Donohue JF, Goodin T, Tosiello R, et al. Dose selection for glycopyrrolate/eFlow((R)) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies. Respir Res. 2017;18(1):202.
   PubMedGoogle Scholar
• Ferguson GT, Goodin T, Tosiello R, et al. Long-term safety of glycopyrrolate/eFlow((R)) CS in moderate-to-very-severe COPD: results from the Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer (GOLDEN) 5 randomized study. Respir Med. 2017;132:251–260.
   PubMed Web of Science ®Google Scholar
• Fogarty C, Kerwin E, Dunn K, et al. The GOLDEN-1 study: safety and bronchodilatory effects of nebulized glycopyrrolate (EP-101) using high efficiency nebulizer in patients with COPD. Abstract presented at the European Respiratory Society Annual Congress 2012. Abstract number 2951. 2012.
   Google Scholar
• Kerwin E, Donohue JF, Goodin T, et al. Efficacy and safety of glycopyrrolate/eFlow((R)) CS (nebulized glycopyrrolate) in moderate-to-very-severe COPD: results from the glycopyrrolate for obstructive lung disease via electronic nebulizer (GOLDEN) 3 and 4 randomized controlled trials. Respir Med. 2017;132:238–250.
   PubMed Web of Science ®Google Scholar
• Leaker BR, Barnes PJ, Jones CR, et al. Efficacy and safety of nebulized glycopyrrolate for administration using a high efficiency nebulizer in patients with chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2015;79(3):492–500.
   PubMed Web of Science ®Google Scholar
• Pham S, Ferguson GT, Kerwin E, et al. In vitro characterization of the eFlow closed system nebulizer with glycopyrrolate inhalation solution. J Aerosol Med Pulm Drug Deliv. 2017.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Identifier NCT01426009. Study to investigate the dose response, safety and efficacy of nebulized EP-101(SUN101) in patients with chronic obstructive pulmonary disease (COPD): GOLDEN-1 study, 2018 [cited 2018 May 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT01426009
   Google Scholar
• Batterink J, Dahri K, Aulakh A, et al. Evaluation of the use of inhaled medications by hospital inpatients with chronic obstructive pulmonary disease. Can J Hosp Pharm. 2012;65(2):111–118.
   PubMedGoogle Scholar
• Mahler DA. Peak inspiratory flow rate as a criterion for dry powder inhaler use in chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2017;14(7):1103–1107.
   PubMed Web of Science ®Google Scholar
• Price B, Sanjar S, Sharma S, et al. Peak inspiratory flow rate baseline measurements in placebo-controlled phase 3 studies of a novel, nebulized glycopyrrolate formulation. Poster presented at CHEST 2017;54:A809.
   Google Scholar
• Ohar J, Tosiello R, Goodin T, et al. The efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of copd: effect of baseline lung function and age. Oral Presentation at CHEST. 2017;152:A771.
   Google Scholar
• Mapel DW, Dalal AA, Blanchette CM, et al. Severity of COPD at initial spirometry-confirmed diagnosis: data from medical charts and administrative claims. Int J Chron Obstruct Pulmon Dis. 2011;6:573–581.
   PubMed Web of Science ®Google Scholar
• Kerwin EM, Tosiello R, Price B, et al. The effect of background long‑acting beta2‑agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe chronic obstructive pulmonary disease. Oral Presentation at CHEST. 2017;152:2017.
   Google Scholar
• Ferguson GT, Tosiello R, Goodin T Safety and efficacy of nebulized glycopyrrolate/eFlow® CSin phase 3 studies of patients with moderate-to-very-severe chronic obstructive pulmonary disease stratified by cardiovascular risk status. Poster presented at CHEST 2017. Poster number P231. 2017.
   Google Scholar
• Mullerova H, Agusti A, Erqou S, et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013;144(4):1163–1178.
   PubMed Web of Science ®Google Scholar
• Singh S, Loke YK, Furberg CD. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Jama. 2008;300(12):1439–1450.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Wilkinson T. Impact of chronic obstructive pulmonary disease exacerbations on patients and payers. Proc Am Thorac Soc. 2006;3(3):218–221.
   PubMedGoogle Scholar
• Laliberte F, Bookhart BK, Nelson WW, et al. Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism. Patient. 2013;6(3):213–224.
   PubMedGoogle Scholar
• Izquierdo JL, Paredero JM, Piedra R. Relevance of dosage in adherence to treatment with long-acting anticholinergics in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:289–293.
   PubMed Web of Science ®Google Scholar
• Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105(3):435–441.
   PubMed Web of Science ®Google Scholar
• Beier J, Kirsten AM, Mroz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. Copd. 2013;10(4):511–522.
   PubMedGoogle Scholar
• Welte T, Metzenauer P, Hartmann U. Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD–a double-blind, randomised, controlled trial. Pulm Pharmacol Ther. 2008;21(1):4–13.
   PubMed Web of Science ®Google Scholar
• Agusti A, Hedner J, Marin JM, et al. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev. 2011;20(121):183–194.
   PubMedGoogle Scholar
• Mocarski M, Zaiser E, Trundell D, et al. Evaluation of the psychometric properties of the nighttime symptoms of COPD instrument. Int J Chron Obstruct Pulmon Dis. 2015;10:475–487.
   PubMed Web of Science ®Google Scholar
• Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361(9356):449–456.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. Trelegy Ellipta. Highlights of prescribing information. 2017 [cited 2018 Feb 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209482s000lbl.pdf
   Google Scholar
• Pascoe SJ, Lipson DA, Locantore N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48(2):320–330.
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929.
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973.
   PubMed Web of Science ®Google Scholar